| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Unrealized gain (loss) on available-for-sale securities | 73 | - | - | - |
| Comprehensive (loss) income | -26,955 | -12,339 | 46,912 | -23,511 |
| Basic | 82,397,753 | 82,186,768 | 82,148,719 | 82,011,670 |
| Weighted-average number of common shares used in computing net loss per share-diluted | 82,397,753 | 82,186,768 | 82,956,423 | 82,011,670 |
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)